Emergent BioSolutions Inc. (LON:0IGA)

Market Cap	306.10M
Revenue (ttm)	621.58M
Net Income (ttm)	101.82M
Shares Out	n/a
EPS (ttm)	1.84
PE Ratio	3.01
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,264
Average Volume	4,239
Open	8.30
Previous Close	8.28
Day's Range	8.00 - 8.30
52-Week Range	4.04 - 12.71
Beta	2.04
RSI	46.71
Earnings Date	Nov 6, 2025

About Emergent BioSolutions

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of d...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1998
• Employees: 900
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0IGA

Financial Performance

In 2024, Emergent BioSolutions's revenue was $1.04 billion, a decrease of -0.54% compared to the previous year's $1.05 billion. Losses were -$190.60 million, -74.94% less than in 2023.

Financial numbers in USD